You are here
Bristol-Myers Squibb Drug Fails Liver Cancer Trial
The company reported that the study did not meet its primary objective of overall survival, based on a non-inferiority statistical design.
BRISK-FL is a randomized, double-blind, multicenter, phase III study of the investigational agent brivanib versus sorafenib in patients with advanced HCC who have not received prior systemic treatment.
Bristol-Myers Squibb and the lead investigators plan to present the findings of the study at an upcoming scientific meeting.
Brivanib alaninate is the alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity.
Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.
For more information, visit the BMS Web site.